Bionano Genomics R&D Spending Growth & History (BNGO)
Bionano Genomics's r&d spending was $11.4M for fiscal 2025.
View full Bionano Genomics company overviewBionano Genomics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $11.4M | −$13.4M | −54.14% |
| 2024 | 2024-12-31 | $24.8M | −$29.2M | −54.10% |
| 2023 | 2023-12-31 | $54.0M | $5.0M | +10.16% |
| 2022 | 2022-12-31 | $49.0M | $26.6M | +118.13% |
| 2021 | 2021-12-31 | $22.5M | $12.2M | +119.24% |
| 2020 | 2020-12-31 | $10.3M | $1.2M | +12.94% |
| 2019 | 2019-12-31 | $9.1M | −$403,272 | −4.25% |
| 2018 | 2018-12-31 | $9.5M | −$2.5M | −21.03% |
| 2017 | 2017-12-31 | $12.0M | — | — |
Bionano Genomics quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.0M | $57,000 | +1.94% |
| Q1 2026 | 2026-03-31 | $3.1M | $769,000 | +32.45% |
| Q4 2025 | 2025-12-31 | $3.2M | −$247,000 | −7.11% |
| Q3 2025 | 2025-09-30 | $2.8M | −$1.9M | −39.71% |
| Q2 2025 | 2025-06-30 | $2.9M | −$3.9M | −57.09% |
| Q1 2025 | 2025-03-31 | $2.4M | −$7.4M | −75.76% |
| Q4 2024 | 2024-12-31 | $3.5M | −$8.2M | −70.29% |
| Q3 2024 | 2024-09-30 | $4.7M | −$9.1M | −65.78% |
| Q2 2024 | 2024-06-30 | $6.8M | −$7.8M | −53.24% |
| Q1 2024 | 2024-03-31 | $9.8M | −$4.2M | −29.83% |
| Q4 2023 | 2023-12-31 | $11.7M | −$2.3M | −16.49% |
| Q3 2023 | 2023-09-30 | $13.8M | $1.0M | +8.19% |
| Q2 2023 | 2023-06-30 | $14.6M | $2.8M | +24.16% |
| Q1 2023 | 2023-03-31 | $13.9M | $3.4M | +32.39% |
| Q4 2022 | 2022-12-31 | $14.0M | $4.8M | +52.03% |
| Q3 2022 | 2022-09-30 | $12.7M | $6.2M | +95.88% |
| Q2 2022 | 2022-06-30 | $11.8M | $7.7M | +187.98% |
| Q1 2022 | 2022-03-31 | $10.5M | $7.8M | +293.09% |
| Q4 2021 | 2021-12-31 | $9.2M | $6.3M | +220.33% |
| Q3 2021 | 2021-09-30 | $6.5M | $4.2M | +182.34% |
| Q2 2021 | 2021-06-30 | $4.1M | $1.7M | +70.18% |
| Q1 2021 | 2021-03-31 | $2.7M | $4,000 | +0.15% |
| Q4 2020 | 2020-12-31 | $2.9M | $478,109 | +19.93% |
| Q3 2020 | 2020-09-30 | $2.3M | $130,000 | +5.98% |
| Q2 2020 | 2020-06-30 | $2.4M | −$7,000 | −0.29% |
| Q1 2020 | 2020-03-31 | $2.7M | $574,000 | +27.33% |
| Q4 2019 | 2019-12-31 | $2.4M | −$114,216 | −4.54% |
| Q3 2019 | 2019-09-30 | $2.2M | −$331,137 | −13.22% |
| Q2 2019 | 2019-06-30 | $2.4M | $309,174 | +14.73% |
| Q1 2019 | 2019-03-31 | $2.1M | −$267,093 | −11.28% |
| Q4 2018 | 2018-12-31 | $2.5M | — | — |
| Q3 2018 | 2018-09-30 | $2.5M | −$461,936 | −15.57% |
| Q2 2018 | 2018-06-30 | $2.1M | — | — |
| Q1 2018 | 2018-03-31 | $2.4M | — | — |
| Q3 2017 | 2017-09-30 | $3.0M | — | — |
Bionano Genomics r&d spending trends
Over the last five fiscal years, Bionano Genomics's r&d spending increased from $10.3M to $11.4M, a change of $1.1M. The latest reported quarter, Q2 2026, shows $3.0M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bionano Genomics source filings ↗